<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>14(17)</volume><submitter>Pura L</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>Chronic kidney disease (CKD) is largely driven by inflammation. Mesenchymal stem cells (MSCs) show therapeutic potential; however, their efficacy across CKD etiologies remains unclear.&lt;h4>Methods&lt;/h4>Comprehensive searches were conducted in PubMed, Cochrane, ScienceDirect, Scopus and Google Scholar. Effect sizes for inflammation and renal function outcomes were meta-analyzed.&lt;h4>Results&lt;/h4>Of 2514 studies screened, 52 met inclusion criteria (49 animal studies, 3 randomized controlled trials). In animal models, MSCs significantly reduced interleukin-6 (mean difference [MD] = -155.80; 95% CI: -249.10, -62.51; &lt;i>p&lt;/i> = 0.001) and tumor necrosis factor-α (TNF-α) (MD = -35.53; 95% CI: -52.75, -18.30; &lt;i>p&lt;/i> &lt; 0.0001). In patients, TNF-α reduction was not significant (MD </pubmed_abstract><journal>Cells</journal><pagination>1313</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12428256</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.</pubmed_title><pmcid>PMC12428256</pmcid><pubmed_authors>Putri RD</pubmed_authors><pubmed_authors>Prahmana MA</pubmed_authors><pubmed_authors>Bandiara R</pubmed_authors><pubmed_authors>Pura L</pubmed_authors><pubmed_authors>Faried A</pubmed_authors><pubmed_authors>Wijaya MP</pubmed_authors><pubmed_authors>Supriyadi R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Mesenchymal Stem Cells as Anti-Inflammatory Agents in Chronic Kidney Disease: A Systematic Review and Meta-Analysis.</name><description>&lt;h4>Background&lt;/h4>Chronic kidney disease (CKD) is largely driven by inflammation. Mesenchymal stem cells (MSCs) show therapeutic potential; however, their efficacy across CKD etiologies remains unclear.&lt;h4>Methods&lt;/h4>Comprehensive searches were conducted in PubMed, Cochrane, ScienceDirect, Scopus and Google Scholar. Effect sizes for inflammation and renal function outcomes were meta-analyzed.&lt;h4>Results&lt;/h4>Of 2514 studies screened, 52 met inclusion criteria (49 animal studies, 3 randomized controlled trials). In animal models, MSCs significantly reduced interleukin-6 (mean difference [MD] = -155.80; 95% CI: -249.10, -62.51; &lt;i>p&lt;/i> = 0.001) and tumor necrosis factor-α (TNF-α) (MD = -35.53; 95% CI: -52.75, -18.30; &lt;i>p&lt;/i> &lt; 0.0001). In patients, TNF-α reduction was not significant (MD </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Aug</publication><modification>2026-04-08T19:11:02.627Z</modification><creation>2026-04-08T12:05:49.395Z</creation></dates><accession>S-EPMC12428256</accession><cross_references><pubmed>40940724</pubmed><doi>10.3390/cells14171313</doi></cross_references></HashMap>